Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience


EKENEL M. , Karabulut S., Cil I., Zirtiloglu A., Aydin E. , Tural D.

ACTAS UROLOGICAS ESPANOLAS, cilt.44, ss.27-33, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 44 Konu: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.acuro.2019.06.007
  • Dergi Adı: ACTAS UROLOGICAS ESPANOLAS
  • Sayfa Sayıları: ss.27-33

Özet

Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.